Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Comi
B Colombo
V Martinelli

Showing results (681-690 of 697) with videos related to

Pageof 70
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 15, 2011
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological SocietyA Ghezzi, L M E Grimaldi, M G Marrosu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 21, 2010
Three years of experience: the Italian registry and safety data updateG L Mancardi, G Tedeschi, M P Amato, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
The pharmacovigilance program on natalizumab in Italy: 2 years of experienceG Tedeschi, M P Amato, R D'Alessandro, et al.
Journal of the Neurological Sciences|July 21, 2009
Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatmentM Trojano, F Pellegrini, D Paolicelli, et al.
European Journal of Neurology|January 21, 2018
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosisX Montalban, R Gold, A J Thompson, et al.
Mediators of Inflammation|November 12, 2021
Topical Administration of 15-Deoxy-<i>Δ</i> <sup>12,14</sup>-Prostaglandin J<sub>2</sub> Using a Nonionic Cream: Effect on UVB-Induced Skin Oxidative, Inflammatory, and Histopathological Modifications in MiceClovis M Kumagai, Renata M Martinez, Barbara B Colombo, et al.
Physical Review Letters|April 6, 2019
Longitudinal Phase-Space Manipulation with Beam-Driven Plasma WakefieldsV Shpakov, M P Anania, M Bellaveglia, et al.
The Journal of International Medical Research|January 1, 1982
Indoprofen in rheumatic patients with acute episodes: a multicentre trialU Ambanelli, G Bassi, V Bianchi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 11, 2016
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticityF Patti, S Messina, C Solaro, et al.
Pageof 70

Showing results (681-690 of 697) with videos related to

Sort By:
Pageof 70
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 15, 2011
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological SocietyA Ghezzi, L M E Grimaldi, M G Marrosu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 21, 2010
Three years of experience: the Italian registry and safety data updateG L Mancardi, G Tedeschi, M P Amato, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
The pharmacovigilance program on natalizumab in Italy: 2 years of experienceG Tedeschi, M P Amato, R D'Alessandro, et al.
Journal of the Neurological Sciences|July 21, 2009
Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatmentM Trojano, F Pellegrini, D Paolicelli, et al.
European Journal of Neurology|January 21, 2018
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosisX Montalban, R Gold, A J Thompson, et al.
Mediators of Inflammation|November 12, 2021
Topical Administration of 15-Deoxy-<i>Δ</i> <sup>12,14</sup>-Prostaglandin J<sub>2</sub> Using a Nonionic Cream: Effect on UVB-Induced Skin Oxidative, Inflammatory, and Histopathological Modifications in MiceClovis M Kumagai, Renata M Martinez, Barbara B Colombo, et al.
Physical Review Letters|April 6, 2019
Longitudinal Phase-Space Manipulation with Beam-Driven Plasma WakefieldsV Shpakov, M P Anania, M Bellaveglia, et al.
The Journal of International Medical Research|January 1, 1982
Indoprofen in rheumatic patients with acute episodes: a multicentre trialU Ambanelli, G Bassi, V Bianchi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 11, 2016
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticityF Patti, S Messina, C Solaro, et al.
Pageof 70